The Effectiveness and Side Effects of Remdesivir in COVID-19 Patients with Pneumonia

Authors

  • Didik Hasmono
  • Tis’a Febriyanti
  • Eka Putri Nurhidayah
  • Arina Dery Puspitasari
  • Ruddy Hartono
  • Mohammad Subkhan

DOI:

https://doi.org/10.37506/ijfmt.v16i4.18573

Keywords:

antiviral, COVID-19, pneumonia, remdesivir

Abstract

Background: Remdesivir is one of the antiviral agents to treat COVID-19 infection. It has an antiviral activity
directly related to activation of pro-inflammatory responses, causing cytokine storm, multiorgan damage and
mortality. With these potential activities, this study investigated the effectiveness and evaluated side effects of
remdesivir used for COVID-19 patients with pneumonia.
Methods: This cohort observational study collected data retrospectively from medical records of COVID-19
patients at Bhayangkara H.S Samsoeri Mertojoso Hospital, Surabaya. Patients who received remdesivir with
loading dose (1 x 200 mg) IV had to follow maintenance dose (1 x 100 mg) IV. They were analyzed in three groups
from October 2020 to February 2021. The data conveyed PCR/rapid Ag Swab, oxygen saturation, chest X-rays
imaging, BUN, SCr, SGOT and SGPT.
Result: A total of 60 patients were evaluated in three therapeutic groups, and the administration of remdesivir
within 5-9 days was effective. Mostly, the patients (77%) had negative PCR/rapid Ag Swab; most of them (52%)
had better oxygen saturation by supplementary oxygen therapy; more than a half had better chest X-rays imaging
parameters (68%). Common side effects included an increase in SGOT (85.30%), SGPT (79.88%), BUN (74.23%),
and serum creatinine (43.33%).
Conclusion: The antiviral effect of remdesivir with loading dose (1 x 200 mg) IV needs to follow maintenance dose
(1 x 100 mg) IV for 5-9 days. Hence, COVID-19 patients with pneumonia could have clinical improvement with
increased level of liver and kidney function.

Author Biographies

  • Didik Hasmono

    Lecturer and researcher in Department of Pharmacy Practice, Faculty of Pharmacy, Universitas
    Airlangga, Surabaya, Indonesia

  • Tis’a Febriyanti

    Student in Bachelor Program, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

  • Eka Putri Nurhidayah

    Student in Magister Clinical Pharmacy Program, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

  • Arina Dery Puspitasari

    Lecturer and researcher in Department of Pharmacy Practice Clinical Pharmacist in Universitas Airlangga Hospital, Surabaya, Indonesia.

  • Ruddy Hartono

    Clinical Pharmacist in Bhayangkara H.S. Samsoeri Mertojoso Hospital, Surabaya, Indonesia

  • Mohammad Subkhan

    Pulmonologist in Bhayangkara H.S. Samsoeri Mertojoso Hospital, Surabaya, Indonesia.

Downloads

Published

2022-10-10

How to Cite

The Effectiveness and Side Effects of Remdesivir in COVID-19 Patients with Pneumonia. (2022). Indian Journal of Forensic Medicine & Toxicology, 16(4), 182-188. https://doi.org/10.37506/ijfmt.v16i4.18573